Pancragen

Overview

Pancragen is a short synthetic tetrapeptide with the sequence Lys-Glu-Asp-Trp (KEDW). It belongs to the family of "short peptide bioregulators" developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology — the same school that produced Epitalon and Thymalin (and the related tetrapeptide Livagen). It is marketed as a pancreas-targeting "bioregulator" aimed at glucose/insulin metabolism and aging.

The evidence behind Pancragen is small, older (mostly 2005–2015), predominantly Russian, and overwhelmingly preclinical, and it comes almost entirely from Khavinson's own group. The primary data are experiments in chemically-induced (alloxan / streptozotocin) diabetic rats, aged rhesus monkeys, and organotypic / cell-culture differentiation models in which the peptide reportedly normalized glucose tolerance, improved insulin/C-peptide, and stimulated pancreatic islet/acinar differentiation. These findings are biologically plausible but not independently replicated. A single small human study in elderly type-2 diabetes patients (Korkushko et al., 2011) reported improved glucose control, but it is low quality, single-group, from the originating school, and unreplicated — it does not constitute robust clinical evidence.

The chemistry is defined for the free acid (molecular formula C26H36N6O9, PubChem CID 68452877, MW ~576.6 g/mol), but no CAS number was found in a primary source, and the exact form sold or studied (free acid vs amidated KEDW-NH2) is often unstated. Pancragen has no FDA or EMA approval and, outside Russia/Ukraine, is sold only as a research-only chemical.

Chemistry and structure

Pancragen is a linear tetrapeptide (four amino acids) with the sequence:

Lys-Glu-Asp-Trp (one-letter: KEDW)

The molecule is a small, water-soluble peptide with a basic Lys terminus, two acidic residues (Glu, Asp), and a C-terminal tryptophan. An important caveat: the free-acid form (PubChem, C26H36N6O9) and the amidated form (KEDW-NH2, used in several primary papers such as PMID 21246099) differ by one atom-set, and the molecular weight of the amidated form was not independently retrieved from a primary source. Product-specific identity is often unstated.

Mechanism of action

The mechanisms attributed to Pancragen should be read as preclinical findings and hypotheses, not established physiology in humans.

• Gene-regulating peptide bioregulator. Pancragen is proposed to act as a cell-penetrating short peptide that interacts with DNA/chromatin to modulate tissue-specific gene expression in pancreatic cells. [Hypothesis] — this is the Khavinson-school model; a direct peptide-DNA binding mechanism is theoretical and not established by independent structural/binding studies for this specific peptide.
• Pancreatic cell differentiation in aging. The peptide is reported to stimulate differentiation of pancreatic acinar and islet cells in aging cell cultures, via upregulation of lineage transcription factors (e.g., Pdx1, Pax6, Ptf1a, Foxa2, Nkx2.2, Pax4 per secondary summaries). [In vitro] — Khavinson et al., Bull. Exp. Biol. Med. 2013 (PMID 23486591); the transcription-factor list is drawn from vendor/secondary summaries and was not individually re-verified against the primary text.
• Increased insulin biosynthesis / improved glucose handling. In chemically-induced (alloxan / streptozotocin) diabetic rats, the tetrapeptide reportedly increased insulin biosynthesis and improved glucose handling. [Animal] — Khavinson et al., Bull. Exp. Biol. Med. 2005 (PMID 16671579) and 2007 (PMID 18642713, PMID 18225766).
• Corrected glucose tolerance in aged primates. In aged rhesus monkeys the peptide reportedly corrected impaired glucose tolerance and normalized insulin/C-peptide. [Animal] — Goncharova et al., Adv. Gerontol. 2014/2015 (PMID 25946840, PMID 28509500).
• Improved glucose control in elderly diabetics. In elderly type-2 diabetes patients the peptide reportedly improved glucose tolerance and reduced the insulin-resistance index. [Human] — Korkushko et al., Bull. Exp. Biol. Med. 2011 (PMID 22448364); a single small, unreplicated study.

Research and evidence

The evidence base is small, old, and dominated by a single research group, with most studies in animals or cell culture and only one small human report.

Human evidence. There are no well-established human clinical trials of Pancragen. Human data are limited to a single small study (Korkushko et al., 2011, PMID 22448364), which in a group including 33 elderly type-2-diabetes patients reported lower fasting and glucose-tolerance-test glucose and reduced plasma insulin and insulin-resistance index in those given the peptide, versus no change in those not given it. This is a single small, unblinded, uncontrolled-quality report from the originating research school, published in a low-tier Russian journal and not independently replicated; it does not constitute robust clinical evidence. No registered randomized controlled trials, no Western/independent replication, and no regulatory-grade efficacy or safety data were found. Human dosing, pharmacokinetics, oral vs injectable bioavailability, and long-term safety are not established in retrievable primary sources.

Status and regulation

Pancragen has no FDA or EMA approval and is not a licensed medicine in the United States or European Union — no FDA/EMA drug label was found. It has been studied and marketed almost exclusively in Russia/Ukraine within the Khavinson St. Petersburg tradition; in that market related short-peptide bioregulators are typically sold as dietary supplements / parapharmaceuticals rather than as licensed drugs (the precise Russian/EAEU registration status — supplement vs registered drug — was not confirmed from a primary regulatory document). Elsewhere it is sold only as a research reagent ("not for human use"). This regulatory classification is not a statement that it is safe or legal to administer to humans; intending it for human use would make it an unauthorised medicine in most jurisdictions.

On WADA status: no source located states a prohibited-list class code for Pancragen, so its sport-eligibility status is not determinable here — and "unapproved" must not be read as automatically implying any particular WADA class. This is a separate axis from legality. Not medical or legal advice — check your own jurisdiction. (Framing dated 2026-07-08.)

Safety

• No robust human safety data. Human exposure is limited to one small study; there is no characterized safety profile, and an absence of reported adverse events reflects a lack of study, not a demonstration of safety.
• Research-grade material. Product sold as "Pancragen" is a research chemical; its identity, purity, and contaminant profile cannot be assumed to be controlled — and even the exact molecular form (free acid vs amidated) is often unstated.
• Injectable-product risks. Where peptides like this are reconstituted and injected in unregulated settings, the usual risks of non-sterile injectables apply.
• Unverified identity. No CAS number could be confirmed and vendor-cited identifiers were not verifiable, underscoring how loosely such material can be characterized.

Legal status

Pancragen is best described by its regulatory classification: a research reagent with no marketing authorisation as a medicine in the US or EU. It has no FDA or EMA approval; in Russia/Ukraine, related bioregulators are typically handled as supplements/parapharmaceuticals rather than licensed drugs, and the precise registration status was not confirmed from a primary regulatory document.

The absence of a specific ban is not affirmative permission to use it: a compound becomes an unauthorised medicine the moment it is intended for human use. Sport anti-doping (WADA) is a separate axis and is not determinable for Pancragen from the sources found. This is not legal advice and status varies by country — verify the position in your own jurisdiction. (Framing dated 2026-07-08.)

How it compares

Pancragen sits within the Khavinson "short peptide bioregulator" family and is best understood next to its cousins:

• Livagen (Lys-Glu-Asp-Ala, KEDA) is another synthetic Khavinson tetrapeptide, promoted as a liver/anti-aging bioregulator. Like Pancragen, its evidence is thin, older, and single-group-dominated — though Pancragen has a slightly broader preclinical footprint (diabetic rats, aged monkeys) plus one small human report.
• Epitalon (Ala-Glu-Asp-Gly, AEDG) is the best-known Khavinson tetrapeptide, promoted for telomerase/anti-aging effects; it shares the same pattern of bold bioregulator claims resting largely on one research school with limited independent replication.

Across the family, the honest reading is the same: bold bioregulator claims, thin and mostly single-group preclinical evidence, and no Western regulatory approval.

Common misconceptions

• "Pancragen is a proven diabetes / glucose-metabolism treatment." It is not. Almost all evidence is older, single-group preclinical work; the only human data are one small, unblinded, unreplicated study.
• "The human study proves it works in people." No — it is a single small report from the originating research school in a low-tier journal, without randomization/blinding and without independent replication. That does not establish clinical efficacy.
• "The transcription factors it activates are well documented (Pdx1, Pax6, Ptf1a…)." That list comes from vendor/secondary summaries and was not individually re-verified against the primary text; treat it as unconfirmed detail on top of an already-weak in vitro claim.
• "Pancragen has a confirmed CAS number." No CAS was found in a primary source; the PubChem record (CID 68452877) lists only a SCHEMBL identifier. Vendor-quoted CAS numbers were not verifiable and are not reported here.
• "The peptide directly reprograms pancreatic genes." The peptide-DNA / gene-regulation mechanism is a Khavinson-school hypothesis without independent structural or binding confirmation for this peptide.
• "No specific ban means it's legal to take." No. Absence of a ban is not permission; any intended human use would make it an unauthorised medicine, and it has no FDA/EMA approval.

Russian research

Much of pancragen's evidence base comes from Russian research — almost entirely from Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology (with primate work led by Goncharova's Sochi group, still co-authored by Khavinson). It is surfaced here for completeness and framed honestly for quality: this is a small, old (mostly 2005–2015), single-institution body of work, dominated by preclinical models, and largely unreplicated outside Russia.

Animal (chemically-induced diabetes in rats). [Animal] The founding tetrapeptide paper reported that KEDWa (amidated Lys-Glu-Asp-Trp-NH2) partially restored insulin synthesis in alloxan-diabetic rats, with a glucose curve resembling that of normal animals; it proposes preproinsulin-gene promoter activation via complementary DNA interaction — a hypothesis, not demonstrated binding (Khavinson VK. Bull Exp Biol Med. 2005;140(4):452-4; PMID 16671579; doi:10.1007/s10517-005-0517-6). [Animal] A later paper reported effects of pancragen on blood glucose and on capillary permeability/leukocyte adhesion in rats with experimental diabetes (Khavinson VKh, Gavrisheva NA, Malinin VV, Chefu SG, Trofimov EL. Bull Exp Biol Med. 2007;144(4):559-62; PMID 18642713; doi:10.1007/s10517-007-0377-3). [Animal] A parallel report described effects on the functional morphology of the pancreas in the same rat model (Kvetnoi IM, Ryzhak AP, Kostyuchek IN, Tafeev YuA. Bull Exp Biol Med. 2007;143(3):368-71; PMID 18225766; doi:10.1007/s10517-007-0114-y). [Animal]/[characterization] A characterization study of the endogenous amidated tetrapeptide (KEDW-NH2) confirms that several primary papers used the amidated form — chemically distinct from the free acid catalogued as PubChem CID 68452877 (Khavinson VKh, Gapparov MM, Sharanova NE, Vasilyev AV, Ryzhak GA. Bull Exp Biol Med. 2010;149(3):351-3; PMID 21246099; doi:10.1007/s10517-010-0944-x).

Animal (aged primates). [Animal] In old female rhesus monkeys, pancragen 50 µg/animal/day i.m. for 10 days was reported to improve glucose clearance and normalize insulin/C-peptide versus baseline, with a partial effect persisting ~3 weeks after discontinuation — but this was an uncontrolled before/after design with sample size not even stated in the abstract (Goncharova ND, Ivanova LG, Oganian TE, Vengerin AA, Khavinson VKh. Adv Gerontol. 2014;27(4):662-7; PMID 25946840). The dose is noted only for context, NOT as guidance. [Animal] A follow-up in 9 old female rhesus monkeys (5 pancragen, 4 glimepiride comparator) reported that pancragen restored insulin and C-peptide and improved glucose tolerance, while glimepiride gave a stronger hypoglycemic effect but normalized hormones less well; with only 5 animals in the pancragen arm, the authors' "effective and safe" language is a small-study conclusion, not established fact (Goncharova ND, Ivanova LG, Oganyan TE, Vengerin AA, Khavinson VK. Adv Gerontol. 2015;28(3):579-585; PMID 28509500).

In vitro (aging pancreatic cells). [In vitro] Pancragen reportedly enhanced activation of differentiation genes in young and aged pancreatic cell cultures; the transcription factors Pdx1, Ptf1a, Pax6, Pax4, Foxa2 and Nkx2.2 are named in the primary abstract, with acinar/islet differentiation proposed as a possible mechanism — still an in vitro claim (Khavinson VKh, Durnova AO, Polyakova VO, Tolibova GH, Linkova NS, Kvetnoy IM, Kvetnaia TV, Tarnovskaya SI. Bull Exp Biol Med. 2013;154(4):501-504; PMID 23486591; doi:10.1007/s10517-013-1987-6). [In vitro] Applied to cultured aging pancreatic cells, pancragen (Lys-Glu-Asp-Trp) was reported to stimulate tissue-specific differentiation factors (e.g. CXCL12, Hoxa3), with effects more pronounced in aged cultures (Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM. Bull Exp Biol Med. 2012;153(1):148-51; PMID 22808515; doi:10.1007/s10517-012-1664-1). [In vitro] The amidated form (H-Lys-Glu-Asp-Trp-NH2) was reported to increase expression of MMP2, MMP9, serotonin, CD79alpha, anti-apoptotic Mcl1, and proliferation markers PCNA and Ki67, while decreasing pro-apoptotic p53, in aged pancreatic cell cultures (Khavinson VKh, Sevost'ianova NN, Durnova AO, Lin'kova NS, Tarnovskaia SI, Dudkov AV, Kvetnaia TV. Adv Gerontol. 2012;25(4):680-4; PMID 23734516; no English DOI retrieved).

Human. [Human] The only human study reported that in elderly type-2 diabetics, pancragen lowered fasting and OGTT glucose and reduced plasma insulin and the insulin-resistance index (the same paper notes nocturnal melatonin was ~70% lower in DM2 versus healthy) (Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA, Bondarenko EV. Bull Exp Biol Med. 2011;151(4):454-6; PMID 22448364; doi:10.1007/s10517-011-1354-4). It enrolled 30 healthy controls plus 33 type-2 diabetics, is single-group, from the originating school, published in a low-tier translated Russian journal, and has never been independently replicated.

Unverifiable vendor/secondary claims. Several circulating claims could not be tied to any verifiable primary source and should be treated as vendor copy, not evidence: that pancragen "improved glucose-stimulated insulin secretion by 40–50% in streptozotocin-induced diabetes models"; mechanistic specifics that it acts "via PDX-1 and MafA" or modulates "GLUT2 transporter and glucokinase" and named beta-cell survival pathways against glucotoxicity/lipotoxicity (only Pdx1 appears in a verifiable primary abstract, PMID 23486591; MafA/GLUT2/glucokinase do not — they trace to aggregator/vendor pages, not to any Khavinson primary paper); and the narrative that the KEDW sequence "was selected through systematic screening of pancreas-derived peptide fractions for insulin-gene promoter activity." A KEDW–DNA interaction paper exists but was published in a non-indexed low-tier journal with no PMID/DOI, so demonstrated DNA binding remains a hypothesis rather than a verifiable primary result. No independently verifiable open Russian full text (CyberLeninka/eLIBRARY) specifically on панкраген and the pancreas could be retrieved, and no CAS number for the peptide was found in any primary or registry source.

Regulatory (registry-grade). In Russia, Панкраген (Pancragen) is NOT a registered medicine: the RLS registry classifies it as a БАД — a dietary supplement (biologically active food additive) in the "proteins, amino acids and derivatives" category — described as a source of peptides with tissue-specific action on pancreatic cells, composed of peptide complex АКС-П (Lys, Glu, Asp, Trp), 100 µg per 0.2 g capsule, sold without prescription. This is a regulatory fact, not evidence of efficacy: being sold as a supplement does NOT make it a proven or approved drug, and the Russian oral supplement capsule is a distinct product from the synthetic research-grade injectable "Pancragen" sold outside Russia (identity/purity uncontrolled). No FDA or EMA approval was found; outside Russia it is sold only as a research reagent ("not for human use"). No source states a WADA prohibited-list class, so sport-eligibility is not determinable.

Quality. The evidence is small, single-group, and under-replicated: the strongest human datum is one unblinded, unreplicated single-group study of 33 diabetics from the originating school; the primate work rests on as few as 5 treated animals or an uncontrolled before/after design; and much of the mechanistic support is in vitro. Several primary papers used the amidated peptide (KEDW-NH2), which differs from the free acid on PubChem CID 68452877 — so even the studied molecule is not always the molecule sold. There are no registered randomized controlled trials, no independent Western replication, and no regulatory-grade efficacy or safety data. This is best read as biologically-plausible preclinical signal from a single research school, not established efficacy in humans; Russian supplement registration is a regulatory fact and must be kept strictly separate from proof of benefit.